Bridget Life Sciences Reports 0.01% Decrease in Enzychem Lifesciences Stake and Changes in Collateral Loans – Minimal Impact on Shareholder Value
Bridget Life Sciences, the largest shareholder of Enzychem Lifesciences, reported a decrease of 7,200 shares due to the termination of a special relationship following a related company executive's resignation, resulting in a 0.01%p drop in ownership from 21.56% to 21.55% with no actual change in beneficial ownership.
Key contracts totaling 9,831,255 shares remain in place, including pledge agreements with Woori Bank and Hana Bank for Son Ki-young and stock loan agreements with individuals for Lee Jong-jin and Joo Soo-yang, with some collateral loan terms modified.
The filer Bridget Life Sciences shows a stable financial position with total assets of approximately 4.25 billion KRW, liabilities of 0.48 billion KRW, and equity of 3.77 billion KRW, though the high interest rates on collateral loans up to 12% pose repayment burden on borrowers.
[AI Summary]This filing is a formal ownership change due to special relationship termination without actual share movement, limiting the impact on stock price. However, multiple collateral loan contracts from the largest shareholder group could trigger margin calls or disposal risks if the stock price declines, representing potential investment risk.